NDAINJECTIONINJECTABLE
Approved
Dec 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
COGENTIN (benztropine mesylate) by Molecular Devices is clinical pharmacology benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. Approved for parkinson's disease. First approved in 1959.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COGENTIN (benztropine mesylate) is an anticholinergic and antihistaminic agent approved in 1959 for managing Parkinson's disease. It is administered via injection and works by blocking cholinergic activity in the brain, thereby reducing motor symptoms associated with dopamine deficiency. The drug's anticholinergic potency approximates that of atropine in laboratory models.
LOE Approaching
As COGENTIN approaches loss of exclusivity, brand team size is likely contracting; career growth is limited to defensive positioning and transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. In the isolated guinea pig ileum, the anticholinergic activity of this drug is about…
Indications (1)
Career Relevance
COGENTIN offers limited career growth given its LOE-approaching status and minimal linked job openings; roles are primarily defensive in nature, focused on maximizing revenues from an established but declining franchise. Professionals joining this product should expect a stable but non-growth environment with emphasis on retention and cost management.
Worked on COGENTIN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.